Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Practical management of Sjögren's disease in the era of new treatment options : Current value of available outcome parameters].

Zeitschrift fur Rheumatologie·2026
Same author

[Management of systemic lupus erythematosus-Including secondary antiphospholipid syndrome, fertility and pregnancy : S3 guidelines of the German Society for Rheumatology and Clinical Immunology and the German Society for Neurology (DGN), German Society for Internal Medicine (DGIM), German Cardiac Society (DGK), Society for Thrombosis and Hemostasis Research (GTH), German Society for Hematology and Medical Oncology (DGHO), German Society for Pediatric and Adolescent Medicine (DGKJ), Society for Pediatric and Adolescent Rheumatology (GKJR), German Society for Nephrology (DGfN), German Society for Pneumology and Ventilation Medicine (DGP), German Rheumatism League National Association, Lupus Erythematosus Self-help Community, German Dermatological Society (DDG). Version: 1.2].

Zeitschrift fur Rheumatologie·2025
Same author

[Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].

Zeitschrift fur Rheumatologie·2023
Same author

Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination.

Journal of autoimmunity·2022
Same author

[80 milestones in rheumatology from 80 years-IV. 2000-2020].

Zeitschrift fur Rheumatologie·2021
Same author

[Current state, goals and quality standards of outpatient care in rheumatology: position paper of the Professional Association of German Rheumatologists (BDRh)].

Zeitschrift fur Rheumatologie·2020
Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026
Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026
Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026
Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026
Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026
Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

[Rituximab].

E Feist1, T Dörner

  • 1Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charite-Universitätsmedizin Berlin, 10098 Berlin, Deutschland.

Zeitschrift Fur Rheumatologie
|August 10, 2010
PubMed
Summary
This summary is machine-generated.

Rituximab effectively treats rheumatoid arthritis (RA) in patients unresponsive to TNF blockers, showing benefits in disease activity and function. While generally safe, careful monitoring for progressive multifocal leukoencephalopathy (PML) and infections, especially with low IgG, is crucial.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Context:

  • Rheumatoid arthritis (RA) treatment often involves biologic agents.
  • Tumor necrosis factor (TNF) blockers are a common first-line biologic therapy.
  • Some patients exhibit inadequate response or contraindications to TNF blockers.

Purpose:

  • To evaluate the efficacy and safety of rituximab in rheumatoid arthritis (RA) patients with prior inadequate response or contraindication to TNF blockers.
  • To review clinical trial data and registry findings on rituximab's impact on RA activity, radiological progression, and functional indices.
  • To assess the safety profile of rituximab in this specific patient population.

Summary:

  • Rituximab, a CD20-targeting monoclonal antibody, demonstrates efficacy in managing RA activity, slowing radiological progression, and improving functional outcomes in patients previously treated with TNF blockers.
  • Safety data indicate that rituximab does not significantly increase the overall risk of infections, including severe cases.
  • The incidence of progressive multifocal leukoencephalopathy (PML) is estimated at 1:15,000-20,000 RA patients; low IgG levels pre-treatment are linked to higher infection risk, warranting consideration of alternative therapies.

Impact:

  • Provides evidence supporting rituximab as a viable treatment option for a specific subset of RA patients.
  • Highlights the importance of monitoring for rare but serious side effects like PML.
  • Informs clinical decision-making regarding patient selection and risk assessment, particularly concerning pre-existing low IgG levels.